Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. (Q40376817)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7490240%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

review article

1 reference

title

Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7490240%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

1 reference

Demetri GD

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7490240%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

Elias AD

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7490240%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

publication date

1 August 1995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7490240%20AND%20SRC:MED&resulttype=core&format=json

Hematology / Oncology Clinics of North America

19 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7490240%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7490240%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7490240%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

page(s)

765-785

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7490240%20AND%20SRC:MED&resulttype=core&format=json

Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group

19 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Cancer statistics, 1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group Study (7613).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Protected environment - prophylactic antibiotic program for malignant sarcomas: randomized trial during remission induction chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

High-dose cisplatin for metastatic soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Altered expression of the retinoblastoma gene product in human sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Rapid Delivery of Multiple High-Dose Chemotherapy Courses With Granulocyte Colony-Stimulating Factor and Peripheral Blood-Derived Hematopoietic Progenitor Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

The Ewing Family of Tumors -- A Subgroup of Small-Round-Cell Tumors Defined by Specific Chimeric Transcripts

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

The use of hematopoietic growth factors to support cytotoxic chemotherapy for patients with breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Randomized study of systemic chemotherapy following complete excision of nonosseous sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

High-dose ifosfamide with mesna uroprotection: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Diagnostic relevance of clonal cytogenetic aberrations in malignant soft-tissue tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

A randomized trial for the treatment of high-grade soft-tissue sarcomas of the extremities: preliminary observations

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

A randomized, prospective trial of adjuvant chemotherapy in adults with soft tissue sarcomas of the head and neck, breast, and trunk

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Phase II trial of carboplatin in soft-tissue sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Alternatives to CYVADIC combination therapy of soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Malignant peripheral neuroectodermal tumors. A retrospective analysis of 42 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Ewing's sarcoma and the "peanut" tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Epirubicin and DTIC (EDIC) for advanced soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

p53 status and the efficacy of cancer therapy in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Treatment of peripheral neuroepithelioma in children and young adults

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Dose response evaluation of adriamycin in human neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Cyvadic in advanced soft tissue sarcoma: A randomized study comparing two schedules: A study of the EORTC soft tissue and bone sarcoma group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Goals of palliative cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthermia in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcom

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Chemotherapy of sarcoma. A comparison of three regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Increased expression of the multidrug-resistance gene in undifferentiated sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2818%2930070-4

7 January 2021

10.1016/S0889-8588(18)30070-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7490240%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

1 reference